Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014
CME ACTIVITY - Research

Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009

Russell S. Barlow, Emilio E. DeBessComments to Author , Kevin L. Winthrop, Jodi A. Lapidus, Robert Vega, and Paul R. Cieslak
Author affiliations: Oregon Health Authority, Portland, Oregon USA (R.S. Barlow, E.E. DeBess, P.R. Cieslak); Oregon Health and Science University, Portland (R.S. Barlow, K.L. Winthrop, J.A. Lapidus); Oregon State Public Health Lab, Hillsboro, Oregon, USA (R. Vega)

Main Article

Table 3

Associations of salmonellosis with CIR, Oregon, 2004–2009*

Variable No. patients % CIR isolates Odds ratio (95%CI) Adjusted odds ratio(95% CI)
Patient travel history
No international travel 1,571 16.2 Referent
Travel to Asia
46
39.1
3.3 (1.8–6.1)
5.2 (2.6–10.4)
Case type
Sporadic 1407 18.6 Referent
Outbreak
406
10.8
0.5 (0.4–0.8)
0.5 (0.4–0.7)
Year (odds of CIR cases/y)
1,813
16.8
1.0 (0.9–1.1)
1.1 (1.0–1.2)
Salmonella serotype
Enteritidis 334 6.0 Referent
Typhimurium 260 25.0 5.2 (3.1–8.9) 6.2 (3.6–10.7)
Heidelberg 149 27.5 6.0 (3.3–10.6) 7.4 (4.1–13.5)
Typhimurium var. Copenhagen 92 53.3 17.9 (9.7–32.9) 20.2 (10.7–38.0)
Newport 82 41.5 11.1 (5.9–20.9) 10.8 (5.6–20.5)
I 4, 5, 12:i:- 79 19.0 3.7 (1.8–7.6) 4.1 (2.0–8.7)
Montevideo 72 4.2 0.7 (0.2–2.4) 0.8 (0.2–2.7)
Saintpaul 52 15.4 2.9 (1.2–6.9) 3.4 (1.4–8.3)
Paratyphi B var. L+ Tartrate+ 50 24.0 5.0 (2.2–10.9 5.8 (2.6–13.1)
All other
643
9.0
1.6 (0.9–2.6)
1.5 (0.9–2.5)
Patient age, y
18–64 999 16.0 Referent
<1 122 18.9 1.2 (0.8–2.0) 1.4 (0.9–2.4)
1–4 220 16.4 1.0 (0.7–1.5) 0.8 (0.5–1.2)
5–17 279 20.1 1.3 (0.9–1.8) 1.0 (0.7–1.5)
>65
193
15.5
1.0 (0.6–1.5)
0.9 (0.6–1.4)
Patient race
White 1,662 16.7 Referent
Not white 151 18.5 1.1 (0.7–1.8) 1.0 (0.6–1.6)

*Multiple logistic regression analysis of 1,813 patients; CIR, clinically important resistance to >1 of the following: ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Boldface indicates statistical significance at p<0.05.

Main Article

Page created: March 18, 2014
Page updated: March 18, 2014
Page reviewed: March 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external